WuXi STA breaks ground on new Delaware manufacturing facility

By BioPharma-Reporter

- Last updated on GMT

The ground-breaking ceremony. Pic: WuXi STA
The ground-breaking ceremony. Pic: WuXi STA

Related tags: Wuxi, Delaware, Us

CRDMO WuXi STA has begun construction of a new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.

The new Delaware campus, which will become Wuxi STA’s second facility in the US, is expected to begin operations in 2025.

Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage and distribution services for clinical trial materials and commercial drug products.

The site is located in the Middletown Business Center at 1091 Industrial Drive, and will create approximately 500 full-time jobs by 2026.

WuXi STA has 12 sites across the US, Europe and Asia that offer a range of services. Together with three other drug product manufacturing sites in Couvet (Switzerland), Wuxi City (China) and Shanghai (China), this new facility will further enhance the company’s global drug production capacity and capabilities.

The Delaware site is one of the most significant private sector investments ever made in the Middletown region, according to Senator Chris Coons: helping ‘further cement the First State as a world leader in biopharmaceutical research and manufacturing’.

Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, said: “I would like to thank our federal, state and local partners in Delaware for their continued support in the establishment of this site.

“WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients.”

Related topics: Upstream Processing, Facilities

Related news

Show more

Related product

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars